Related references
Note: Only part of the references are listed.Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients
P. Kopelman et al.
INTERNATIONAL JOURNAL OF OBESITY (2007)
Effect of weight loss and nutritional intervention on arterial stiffness in type 2 diabetes
Emma Barinas-Mitchell et al.
DIABETES CARE (2006)
A randomized trial of lifestyle intervention in primary healthcare for the modification of cardiovascular risk factors - The Bjorknas study
K. Margareta Eriksson et al.
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2006)
Pharmacological therapies for obesity
LM Kaplan
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2005)
Drug insight: appetite suppressants
GA Bray
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2005)
A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with mefformin
SJ McNulty et al.
DIABETES CARE (2003)
The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial
M Hanefeld et al.
DIABETES OBESITY & METABOLISM (2002)
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
JM Miles et al.
DIABETES CARE (2002)
Management of obesity in patients with Type 2 diabetes
L Campbell et al.
DIABETIC MEDICINE (2001)
Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes
KV Williams et al.
DIABETES OBESITY & METABOLISM (2000)
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
K Fujioka et al.
DIABETES OBESITY & METABOLISM (2000)